Evidence map›Paper›PMID 20805505›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2010

Proline-rich tyrosine kinase-2 is critical for CD8 T-cell short-lived effector fate.

Sören Beinke, Hyewon Phee, Jonathan M Clingan, Joseph Schlessinger, Mehrdad Matloubian, Arthur Weiss

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 48 citations in OpenAlex.

  1. Trial
  2. Article
  3. The integrin adhesome and control of anti-tumour immunity.Biochemical Society transactions · 2024
    Review
  4. IL-2 delivery to CD8Nature communications · 2024
    Article
  5. Review
  6. Article
  7. Article
  8. New Insights on the Nuclear Functions and Targeting of FAK in Cancer.International journal of molecular sciences · 2022
    Review
  9. Review
  10. Review
  11. Heparanase, cell signaling, and viral infections.Cellular and molecular life sciences : CMLS · 2020
    Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Sören BeinkeDepartment of Medicine, Division of Rheumatology, The Howard Hughes Medical Institute, Rosalind Russell Medical Research Center for Arthritis, and Graduate Program in Biomedical Sciences, University of California, San Francisco, CA 94143-0795, USA.
Hyewon Phee
Jonathan M Clingan
Joseph Schlessinger
Mehrdad Matloubian
Arthur Weiss
Center for Rheumatology · USHoward Hughes Medical Institute · USYale University · US

Funding

Howard Hughes Medical Institute
6 · The paper itself

Abstract

T-cell interactions with antigen-presenting cells are important for CD8 T-cell effector or memory fate determination. The integrin leukocyte function-associated antigen-1 (LFA-1) mediates T-cell adhesion but the contribution of LFA-1-induced signaling pathways to T-cell responses is poorly understood. Here we demonstrate that proline-rich tyrosine kinase-2 (PYK2) deficiency impairs CD8 T-cell activation by synergistic LFA-1 and T-cell receptor stimulation. Furthermore, PYK2 is essential for LFA-1-mediated CD8 T-cell adhesion and LFA-1 costimulation of CD8 T-cell migration. During lymphocytic choriomeningitis virus infection in vivo, PYK2 deficiency results in a specific loss of short-lived effector CD8 T cells but does not affect memory-precursor CD8 T-cell development. Similarly, lack of LFA-1 primarily impairs the generation of short-lived effector cells. Thus, PYK2 facilitates LFA-1-dependent CD8 T-cell responses and promotes CD8 T-cell short-lived effector fate, suggesting that PYK2 may be an interesting therapeutic target to suppress exacerbated CD8 T-cell responses.

Indexed as

Cell LineageAnimalsCD8-Positive T-LymphocytesCell DifferentiationCells, CulturedCell SurvivalFocal Adhesion Kinase 2Gene Expression Regulation, NeoplasticImmunologic MemoryLymphocyte Function-Associated Antigen-1MiceMice, Inbred C57BLMice, KnockoutReceptors, Antigen, T-CellFocal Adhesion Kinase 2Lymphocyte Function-Associated Antigen-1Ptk2b protein, mouseReceptors, Antigen, T-Cell

Identifiers

PMID20805505
PMCPMC2941278
OpenAlexW2026038112

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.